The constant churn of activity in the anti-inflammatory sector will continue, with novel products set to produce key data as approval is awaited for the first biosimilar version of AbbVie Inc.'s top-selling anti-TNF agent Humira (adalimumab).
Amgen Inc. is leading the race to be first with a highly anticipated biosimilar Humira, with an FDA Biosimilar...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)